Global Dialysis Induced Anemia Treatment Market Size, Share, and COVID-19 Impact Analysis, By Treatment (Erythropoiesis-Stimulating Agents, Iron Supplements, HIF-PH Inhibitors, and Combination Therapies), By Sales Channel (Hospital Pharmacies, Dialysis Centers, Retail Pharmacy Chains, and Mail Order Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035.

Global Dialysis Induced Anemia Treatment Market Insights Forecasts to 2035

• The Global Dialysis Induced Anemia Treatment Market Size Was Estimated at USD 1.87 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 6.81% from 2025 to 2035
• The Worldwide Dialysis Induced Anemia Treatment Market Size is Expected to Reach USD 3.86 Billion by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

The global dialysis induced anemia treatment market size was worth around USD 1.87 billion in 2024 and is predicted to grow to around USD 3.86 billion by 2035 with a compound annual growth rate (CAGR) of 6.81% from 2025 and 2035. Growth in emerging nations, individualized intravenous iron therapy, biosimilar developments, and the incorporation of digital monitoring technologies to enhance anemia management and improve patient outcomes are some of the opportunities for the dialysis-induced anemia treatment market.  

Market Overview

The global industry dedicated to creating, producing, and distributing therapeutic solutions for anemia brought on by dialysis in patients with chronic kidney disease (CKD) is included in the dialysis induced anemia treatment market. The market for dialysis-induced anemia treatment is concentrated on improving hemoglobin control, decreasing reliance on blood transfusions, and developing treatments like ESAs and HIF-PHIs to improve the prognosis of patients with chronic renal disease receiving dialysis.    

The growing incidence of end-stage renal disease (ESRD) and chronic kidney disease (CKD), which greatly raises the need for efficient anemia management among dialysis patients, is the main factor driving the dialysis-induced anemia treatment market. Growing rates of chronic kidney disease, expanding dialysis methods, improvements in injectable iron therapy, and growing use of biosimilars and erythropoiesis-stimulating drugs are some of the major factors propelling the dialysis induced anemia treatment market. 

Report Coverage

This research report categorizes the dialysis induced anemia treatment market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the dialysis induced anemia treatment market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the dialysis induced anemia treatment market. 

Driving Factors

The aging population and rising rates of diabetes and high blood pressure are two more factors driving the dialysis induced anemia treatment market. In hospital pharmacies, automated dispensing systems and electronic medical records are being integrated to streamline anemia management procedures. Erythropoiesis-stimulating agents (ESAs), injectable iron formulations, and newly developed hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are examples of therapeutic approaches that are improving patient outcomes and treatment efficacy. The market for dialysis induced anemia treatment is experiencing steady expansion due to these reasons, which are also encouraging innovation and broadening the therapeutic reach.   

Restraining Factors

The dialysis induced anemia treatment market is constrained by a number of factors, such as high treatment costs, restricted access in low-resource settings, the negative effects of erythropoiesis-stimulating agents, regulatory obstacles, and patient non-compliance with long-term therapies.  

Market Segmentation

The dialysis induced anemia treatment market share is classified into treatment and sales channel. 

• The iron supplements segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the treatment, the dialysis induced anemia treatment market is divided into erythropoiesis-stimulating agents, iron supplements, HIF-PH inhibitors, and combination therapies. Among these, the iron supplements segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. Innovations such as ferric carboxymaltose, iron sucrose, and novel iron complexes that offer lower dose frequency and fewer side effects, as well as the growing prevalence of ESRD and cost-effectiveness in lowering ESA dependency, are driving the expansion of the iron supplements market.

• The hospital pharmacies segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the sales channel, the dialysis induced anemia treatment market is divided into hospital pharmacies, dialysis centers, retail pharmacy chains, and mail order pharmacies. Among these, the hospital pharmacies segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Hospital pharmacies provide clinical supervision, secure storage, and reimbursement alignment to guarantee drug management that is both safe and efficient. Anaemia management is made easier by the combination of automated dispensing systems and electronic medical records (EMRs), which improve workflow efficiency, inventory tracking, and patient compliance monitoring. 

Regional Segment Analysis of the Dialysis Induced Anemia Treatment Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the Dialysis Induced Anemia Treatment market over the predicted timeframe.

North America is anticipated to hold the largest share of the dialysis induced anemia treatment market over the predicted timeframe. The high incidence of chronic kidney disease, the sophisticated healthcare system, the advantageous reimbursement practices, and the extensive use of erythropoiesis-stimulating medicines and injectable iron treatments are the main factors driving North America. The United States is expanding steadily due to a huge patient base in need of continuous dialysis care, growing awareness of the disease, and improvements in dialysis-related anemia therapies. Due to its stable demand for dialysis treatments and its well-established healthcare system, the United Kingdom has relatively moderate growth. 

Asia Pacific is expected to grow at a rapid CAGR in the dialysis induced anemia treatment market during the forecast period. Increased use of injectable iron treatments and erythropoiesis-stimulating medicines, growing dialysis infrastructure, and an increase in the prevalence of chronic renal disease are the main drivers in the Asia Pacific region. China is showing strong development, which is indicative of both its growing healthcare infrastructure and the rising number of patients receiving dialysis as a result of the rising prevalence of chronic renal disease.  

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the dialysis induced anemia treatment market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Novartis
• Amgen
• GSK plc
• Biocon
• Roche
• CSL Vifor
• Akebia Therapeutics
• Teva Pharmaceuticals
• Johnson & Johnson (J&J)
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Development

• In January 2025, Several encouraging business updates were announced today by Akebia Therapeutics®, Inc., a biopharmaceutical company that improves the lives of those affected by kidney disease. Vafseo® pills have been shipped to dialysis facilities since January, and they are now available in the United States for adult patients with anemia from chronic kidney disease (CKD) who have been receiving dialysis for at least three months.

• In February 2023, GSK announced that Jesduvroq, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), has been approved by the US Food and Drug Administration (FDA) to treat anemia caused by chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. The only HIF-PHI authorized in the United States and the first novel medication for treating anemia in more than three decades, Jesduvroq offers patients with CKD anemia receiving dialysis a new, practical oral alternative.  

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the dialysis induced anemia treatment market based on the below-mentioned segments:  

Global Dialysis Induced Anemia Treatment Market, By Treatment

• Erythropoiesis-stimulating Agents
• Iron Supplements
• HIF-PH Inhibitors
• Combination Therapies

Global Dialysis Induced Anemia Treatment Market, By Sales Channel  

• Hospital Pharmacies
• Dialysis Centers
• Retail Pharmacy Chains
• Mail Order Pharmacies

Global Dialysis Induced Anemia Treatment Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa